Bioenergetics in Hypertrophied and Remodeled Left Ventricle

左心室肥厚和重塑的生物能学

基本信息

  • 批准号:
    9162316
  • 负责人:
  • 金额:
    $ 58万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-08-10 至 2017-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The inner layers of the left ventricular wall (ENDO) are known to be the most susceptible to oxidative stresses. We hypothesize that there is transmural gradient of reserves of ATP production rate via both creatine kinase (CK) and ATPase, which is the lowest in ENDO that results in the ENDO vulnerability in LVH hearts. Despite the intense interest in cellular therapy for myocardial repair, the majority of research reports to date have been designed to repair or prevent LV dysfunction in hearts with myocardial infarction secondary to coronary arteries diseases. Given the fact that more than 50% of heart transplant CHF patients whose etiology is nonischemic, studies using nonischemic large animal model is urgently needed before pursuing large scale clinical trials. The mechanisms underlying the beneficial effects of cellular therapy are not well defined. It is a consistent finding that the engraftment rate is low. However, the long term improvement of the LV contractile function of the recipient heart is consistently observed. Therefore, in addition to the myocardial regeneration from the engrafted cells the improved LV chamber function is also likely related to the changes of the recipient myocardial protein deferential expression. Comparing two swine models of LVH secondary to pressure overload or to postinfarction LV remodeling, the effects of MSCs transplantation on LV contractile function (MRI); myocardial perfusion, myocardial oxygenation level (1H-MRS); and ATP turnover rate (31P- MRS) will be measured biweekly for 8 weeks, the recipient myocardial differential protein expression will be examined by comparative proteomics. The specific aims are: SA1. Using the recently developed T1-nom P-31 magnetization saturation transfer (MST) methods to examine whether the myocardial ATP turnover rate via CK and ATPase are most severely altered in the ENDO of LVH hearts, and whether the severity of which is linearly related to the severity of the LV dysfunction. SA2. To examine whether the functional beneficial effects of allogenic MSC transplantation are accompanied by the improvement of ATP production capacity via CK and ATPase in the ENDO of LVH hearts with or without ischemic coronary artery diseases, and whether these functional benefits are accompanied by regeneration of myocardium from both engrafted MSCs as well as endogenous CPCs. SA3: To examine whether the functional beneficial effects of cellular therapy are associated with the differential protein expression profle of the recipient myocardium. We will employ cutting edge liquid chromatography mass spectrometry-based comparative proteomics method to quantitatively determine the changes in the protein expression with a special emphasis on growth factors family proteins and proteins involved in energy metabolism. The findings of the experiments will elucidate for the first time, the transmural gradient of ATP turnover rate via both CK and ATPase in the in vivo LVH hearts. The findings of these studies will advance our understanding of the mechanisms of cellular therapy in myocardial repair, and lead to better diagnostic and therapeutic modalities for CHF patients.
描述(由申请人提供):已知左心室壁(ENDO)的内层对氧化应激最敏感。我们假设存在通过肌酸激酶(CK)和ATP酶的ATP生成率储备的跨壁梯度,这在ENDO中是最低的,导致LVH心脏的ENDO脆弱性。尽管对心肌修复的细胞疗法非常感兴趣,但迄今为止的大多数研究报告都旨在修复或预防继发于冠状动脉疾病的心肌梗死心脏的LV功能障碍。鉴于心脏移植患者中有超过50%的病因是非缺血性CHF,在进行大规模临床试验之前,迫切需要使用非缺血性大型动物模型进行研究。细胞疗法的有益作用的机制尚未明确。这是一个一致的发现,植活率低。然而,一致地观察到受体心脏的LV收缩功能的长期改善。因此,除了移植细胞的心肌再生外,左室功能的改善也可能与受体心肌蛋白差异表达的变化有关。比较两种继发于压力超负荷或梗死后LV重构的LVH猪模型,将每两周测量MSC移植对LV收缩功能(MRI)、心肌灌注、心肌氧合水平(1H-MRS)和ATP周转率(31 P-MRS)的影响,持续8周,将通过比较蛋白质组学检查受体心肌差异蛋白表达。具体目标是:SA 1。采用新近发展的T1-nom P-31磁化饱和度转移(MST)方法,检测左室肥厚心脏ENDO时心肌ATP转换率是否通过CK和ATP酶发生最严重的改变,以及其严重程度是否与左室功能障碍的严重程度呈线性相关。SA 2.研究同种异体MSC移植的功能性有益作用是否伴随着伴有或不伴有缺血性冠状动脉疾病的LVH心脏的ENDO中通过CK和ATP酶的ATP产生能力的改善,以及这些功能性有益作用是否伴随着来自移植的MSC以及内源性CPC的心肌再生。SA3:检查细胞治疗的功能有益作用是否与受体心肌的差异蛋白表达谱相关。我们将采用先进的液相色谱-质谱法为基础的比较蛋白质组学方法来定量确定蛋白质表达的变化,特别强调生长因子家族蛋白质和参与能量代谢的蛋白质。实验结果将首次阐明在体LVH心脏中ATP周转率通过CK和ATP酶的跨壁梯度。这些研究结果将促进我们对细胞治疗心肌修复机制的理解,并为CHF患者提供更好的诊断和治疗方式。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jianyi Zhang其他文献

Jianyi Zhang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jianyi Zhang', 18)}}的其他基金

Project 1 - Endogenous and Exogenous Mechanisms that Promote Myocardial Remuscularization
项目 1 - 促进心肌再肌化的内源性和外源性机制
  • 批准号:
    10677730
  • 财政年份:
    2022
  • 资助金额:
    $ 58万
  • 项目类别:
Core A: Administrative Core
核心A:行政核心
  • 批准号:
    10493835
  • 财政年份:
    2022
  • 资助金额:
    $ 58万
  • 项目类别:
Project 1 - Endogenous and Exogenous Mechanisms that Promote Myocardial Remuscularization
项目 1 - 促进心肌再肌化的内源性和外源性机制
  • 批准号:
    10493838
  • 财政年份:
    2022
  • 资助金额:
    $ 58万
  • 项目类别:
Mechanisms that Govern Cardiomyocyte Proliferation and Remuscularization following Ventricular Injury
心室损伤后控制心肌细胞增殖和再肌化的机制
  • 批准号:
    10677719
  • 财政年份:
    2022
  • 资助金额:
    $ 58万
  • 项目类别:
Core A: Administrative Core
核心A:行政核心
  • 批准号:
    10677720
  • 财政年份:
    2022
  • 资助金额:
    $ 58万
  • 项目类别:
Mechanisms that Govern Cardiomyocyte Proliferation and Remuscularization following Ventricular Injury
心室损伤后控制心肌细胞增殖和再肌化的机制
  • 批准号:
    10493834
  • 财政年份:
    2022
  • 资助金额:
    $ 58万
  • 项目类别:
Bioenergetics in Hypertrophied and Remodeled Left Ventricle
左心室肥厚和重塑的生物能学
  • 批准号:
    8676931
  • 财政年份:
    2012
  • 资助金额:
    $ 58万
  • 项目类别:
Cell Therapy in Hypertrophied and Remodeled Left Ventricle
左心室肥大和重塑的细胞疗法
  • 批准号:
    9391517
  • 财政年份:
    2012
  • 资助金额:
    $ 58万
  • 项目类别:
Endogenous and exogenous mechanisms that promote myocardial remuscularization in post infarction LV remodeling
梗死后左室重构中促进心肌再肌化的内源性和外源性机制
  • 批准号:
    10302748
  • 财政年份:
    2012
  • 资助金额:
    $ 58万
  • 项目类别:
Bioenergetics in Hypertrophied and Remodeled Left Ventricle
左心室肥厚和重塑的生物能学
  • 批准号:
    8528711
  • 财政年份:
    2012
  • 资助金额:
    $ 58万
  • 项目类别:

相似海外基金

HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
  • 批准号:
    10039902
  • 财政年份:
    2022
  • 资助金额:
    $ 58万
  • 项目类别:
    EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
  • 批准号:
    21K15925
  • 财政年份:
    2021
  • 资助金额:
    $ 58万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
  • 批准号:
    21K08410
  • 财政年份:
    2021
  • 资助金额:
    $ 58万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
  • 批准号:
    20K21672
  • 财政年份:
    2020
  • 资助金额:
    $ 58万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
  • 批准号:
    18K16395
  • 财政年份:
    2018
  • 资助金额:
    $ 58万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
  • 批准号:
    17K10951
  • 财政年份:
    2017
  • 资助金额:
    $ 58万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
  • 批准号:
    370541
  • 财政年份:
    2017
  • 资助金额:
    $ 58万
  • 项目类别:
    Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
  • 批准号:
    16K10863
  • 财政年份:
    2016
  • 资助金额:
    $ 58万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
  • 批准号:
    276706135
  • 财政年份:
    2015
  • 资助金额:
    $ 58万
  • 项目类别:
    Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
  • 批准号:
    15H04915
  • 财政年份:
    2015
  • 资助金额:
    $ 58万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了